New chemo cocktail aims to treat rare lymphoma without heart damage
NCT ID NCT07535762
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new chemotherapy combination called CAOP for elderly patients (65+) with untreated peripheral T-cell lymphoma, a rare blood cancer. The standard treatment often causes heart damage, but this regimen replaces the heart-toxic drug with a safer one. The study will enroll 36 participants to see if the combo can achieve complete remission with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aclarubicin, cyclophosphamide, vincristine, and prednisone (CAOP regimen)
- What this could lead to
- If successful, this could offer a safer and effective chemotherapy option for elderly patients with peripheral T-cell lymphoma, potentially improving survival without severe heart damage.
- What could go wrong
- This is a small, early-phase trial with only 36 participants, so results may not apply to all patients. The drug combination may still cause side effects or fail to improve outcomes compared to standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) (ALK-1 NEGATIVE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Shanghai, China
-
Ruijin Hospital Wuxi Branch
Wuxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug boost Chemotherapy's power against a rare lymphoma?
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Promising combo tackles rare blood cancer in chinese patients
- New drug cocktail aims to tackle rare blood cancer
- New drug combo shows promise for rare lymphoma in Real-World study
- Massive T-Cell lymphoma database aims to unlock new insights